Microbiota-Derived Molecule Compositions for Colonic Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current approaches to counter the detrimental effects of microbiome alterations on human health, such as antibiotics, prebiotics, and probiotics, have limited efficacy and potential adverse effects, necessitating the development of pharmaceutical-grade compositions that induce tolerance, strengthen the gut barrier, and maintain or restore metabolic and immune homeostasis.
Innovation Solution
Therapeutic combinations of microbiota-derived molecules, including short-chain fatty acids, GPR109 and GPR43 ligands, histone-deacetylase inhibitors, and antigens from Clostridium Cluster IV, XIVa, and XVIII bacteria, administered orally via colonic delivery systems to induce tolerance, strengthen gut barrier integrity, and reduce inflammation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional approaches (antibiotics, prebiotics, probiotics) are used to counter microbiome alterations, then some therapeutic effect is achieved, but efficacy is limited and adverse effects occur
Solution Approach 1:
The invention changes the chemical parameters of the therapeutic agents by using specifically engineered small molecules with optimized structures. These molecules are designed to interact with particular microbiota components, achieving higher therapeutic efficacy while reducing adverse effects compared to conventional broad-spectrum antibiotics or undefined prebiotic/probiotic mixtures
Solution Approach 2:
The invention employs composite therapeutic compositions containing multiple small molecules with different mechanisms of action working synergistically. These composite formulations address multiple aspects of microbiome dysfunction simultaneously, improving overall therapeutic reliability while minimizing the need for high doses of individual agents that could cause adverse effects
2Area of stationary object
If microbiota-derived molecules are delivered systemically, then broad distribution is achieved, but targeted delivery to the colon is insufficient
Solution Approach 1:
The invention segments the delivery system into multiple components: an oral dosage form containing the small molecules, and a colonic delivery vehicle (such as an enteric-coated capsule or time-release formulation) that ensures the molecules are released specifically in the colon. This segmentation allows the therapeutic agents to reach their intended target site with high precision while still being administered systemically through the oral route
Solution Approach 2:
The invention introduces an intermediary colonic delivery vehicle that acts as a mediator between the orally administered small molecules and the colonic microbiota. This intermediary protects the molecules from degradation in the upper GI tract and ensures their release at the precise anatomical location where they can exert their therapeutic effect on microbiome alterations
3Ease of manufacture
If single-ingredient compositions are used, then manufacturing simplicity is maintained, but synergistic therapeutic effects are not achieved
Solution Approach 1:
The invention merges multiple small molecules with complementary mechanisms of action into a single composite therapeutic composition. These molecules work synergistically to address different aspects of microbiome dysfunction simultaneously, achieving enhanced therapeutic efficacy while being formulated as a single oral dosage form that maintains manufacturing simplicity through established pharmaceutical manufacturing processes
Data Source
AI summary
Compositions consisting of bioactive molecules derived from the microbiota of a mammal are provided herein. When administered orally with a colonic delivery system, the compositions are useful for the prophylaxis and treatment of diseases, in particular inflammatory, autoimmune and infectious diseases. The compositions comprise combinations of small molecules and bacterial antigens formulated in colonic delivery systems. Use of the compositions results in any or all of: induction of immune tolerance; strengthening of the gut mucosal barrier integrity; reduction of inflammation; and amelioration of a disease state caused by inflammation, an autoimmune reaction or an infectious agent.